Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type ...
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc.
Zacks.com on MSN7d
Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 WeeksKeros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...
Hosted on MSN16d
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS)Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Overweight to Neutral. Analyst Price Forecast Suggests 310.14% Upside As ...
Zacks.com on MSN15d
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and ...
Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...
Asteburu honetan, autonomia erkidegoen arteko Espainiako Kros Txapelketa jokatuko dute Cerro de los Angelesen, Getafen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback